Abstract 126P
Background
Treatment of LARC has the main goal to achieve a tumor pathological complete response (pCR) that is strongly related to better disease-free survival (DFS) and overall survival (OS). However, it occurs only in 10-30% of LARC patients with neoadjuvant chemoradiotherapy (nCRT) with a high rate of distant metastasis (DM). TNT can improve patient’s outcomes by delivering systemic chemotherapy and nCRT prior to surgery. Multiple randomized trials (RAPIDO, PRODIGE 23, OPRA, CAO/ARO/AIO-12) evaluated different TNT strategies in terms of CRT sequencing, chemotherapy intensity, and radiotherapy. Overall, as a result from those trials, emerges that TNT increased pCR rate compared with standard nCRT (28,4% vs 14,3% RAPIDO and 27,5% vs 11,7% PRODIGE 23 and 28% vs 14% OPRA). However, there is lack of data about any difference in pathological response according to primary TH from anal verge and TNT.
Methods
This is a retrospective, multicentric, observational study whose aim is to evaluate the impact of TH from anal verge on pathological response (pR) to TNT in LARC through Ryan modified TRG score. Data were collected from 48 LARC patients (cT4N+), treated with induction mFOLFOX followed by long course nCRT and total mesorectal excision (TME). The secondary endpoint was ORR.
Results
The median age was 65 (± 8), 75% were male. All patients had clinical stage III. TH from anal verge were as follows 21% proximal (>10 cm), 46% middle (5-10 cm), and 33% (<5 cm) distal side. After TNT proximal cancers (PC) showed worst TRGs: TRG-4 (3 patients), TRG-3 (5 patients), and TRG-2 (2 patients). Middle cancers (MC) cancer showed: TRG-3 (1 patient), TRG-2 (11 patients), TRG1-0 (10 patients). Distal cancers (DC) showed: TRG2 (2 patients), TRG1-0 (13 patients). ORR was also different according to the TH: 30% PC, 77% for MC, and 80% for DC.
Conclusions
The results of our study show a correlation between rectal TH and responses to TNT. DCs seem to have a poorer pR to TNT. This data is consistent with recent literature about the actual usefulness of radiotherapy (RT) in patients with DCs and could help to a better selection of patients more suitable for TNT with or without RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Pretta: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract